$ALXN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALEXION PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ALEXION PHARMACEUTICALS, INC.. Get notifications about new insider transactions in ALEXION PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 4 5 6 7 8 9 10 11 12 ... 22 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 156.95 | 10 | 1,570 | 113,965 | 114 K to 114 K (-0.01 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 155.55 | 1,600 | 248,880 | 113,975 | 115.6 K to 114 K (-1.38 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Grant | A | 0.00 | 9,745 | 0 | 115,575 | 105.8 K to 115.6 K (+9.21 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | SVP & General Couns ... | Sell | S | 158.56 | 16 | 2,537 | 22,232 | 22.2 K to 22.2 K (-0.07 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | SVP & General Couns ... | Sell | S | 155.55 | 1,020 | 158,661 | 22,248 | 23.3 K to 22.2 K (-4.38 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | SVP & General Couns ... | Grant | A | 0.00 | 6,068 | 0 | 23,268 | 17.2 K to 23.3 K (+35.28 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 157.47 | 20 | 3,149 | 137,900 | 137.9 K to 137.9 K (-0.01 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 155.55 | 1,600 | 248,880 | 137,920 | 139.5 K to 137.9 K (-1.15 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Grant | A | 0.00 | 9,745 | 0 | 139,520 | 129.8 K to 139.5 K (+7.51 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Option Exercise | M | 4.93 | 30,000 | 147,900 | 0 | |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Sell | S | 159.00 | 30,000 | 4,770,000 | 179,217 | 209.2 K to 179.2 K (-14.34 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Buy | M | 4.93 | 30,000 | 147,900 | 209,217 | 179.2 K to 209.2 K (+16.74 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 93.83 | 3,800 | 356,554 | 0 | |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 78.88 | 10,813 | 852,929 | 0 | |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 42.66 | 6,250 | 266,625 | 0 | |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 22.90 | 7,876 | 180,360 | 0 | |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 155.00 | 29,637 | 4,593,735 | 94,818 | 124.5 K to 94.8 K (-23.81 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 93.83 | 3,800 | 356,554 | 124,455 | 120.7 K to 124.5 K (+3.15 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 78.88 | 10,813 | 852,929 | 120,655 | 109.8 K to 120.7 K (+9.84 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 42.66 | 6,250 | 266,625 | 109,842 | 103.6 K to 109.8 K (+6.03 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 22.90 | 7,876 | 180,360 | 103,592 | 95.7 K to 103.6 K (+8.23 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 157.10 | 3,300 | 518,430 | 95,716 | 99 K to 95.7 K (-3.33 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 153.63 | 3,200 | 491,616 | 99,016 | 102.2 K to 99 K (-3.13 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 157.14 | 852 | 133,883 | 102,216 | 103.1 K to 102.2 K (-0.83 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 10.84 | 20,000 | 216,800 | 10,000 | |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 18.08 | 30,000 | 542,400 | 0 | |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 16.83 | 12,276 | 206,605 | 0 | |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 26.64 | 7,932 | 211,308 | 0 | |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 49.43 | 5,572 | 275,424 | 0 | |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 88.40 | 3,237 | 286,151 | 0 | |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Option Exercise | M | 96.35 | 1,712 | 164,951 | 1,713 | |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Sell | S | 159.01 | 13,501 | 2,146,794 | 29,456 | 43 K to 29.5 K (-31.43 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Sell | S | 158.41 | 30,222 | 4,787,467 | 42,957 | 73.2 K to 43 K (-41.30 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Sell | S | 157.35 | 12,322 | 1,938,867 | 73,179 | 85.5 K to 73.2 K (-14.41 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Sell | S | 156.24 | 9,664 | 1,509,903 | 85,501 | 95.2 K to 85.5 K (-10.15 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Sell | S | 155.23 | 15,020 | 2,331,555 | 95,165 | 110.2 K to 95.2 K (-13.63 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 10.84 | 20,000 | 216,800 | 110,185 | 90.2 K to 110.2 K (+22.18 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 18.01 | 30,000 | 540,300 | 90,185 | 60.2 K to 90.2 K (+49.85 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 16.83 | 12,276 | 206,605 | 60,185 | 47.9 K to 60.2 K (+25.62 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 26.64 | 7,932 | 211,308 | 47,909 | 40 K to 47.9 K (+19.84 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 49.43 | 5,572 | 275,424 | 39,977 | 34.4 K to 40 K (+16.20 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 88.40 | 3,237 | 286,151 | 34,405 | 31.2 K to 34.4 K (+10.39 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Buy | M | 96.35 | 1,712 | 164,951 | 31,168 | 29.5 K to 31.2 K (+5.81 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 153.63 | 2,700 | 414,801 | 129,775 | 132.5 K to 129.8 K (-2.04 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 157.14 | 852 | 133,883 | 132,475 | 133.3 K to 132.5 K (-0.64 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | LINK MAX | Director | Sell | S | 157.09 | 3,000 | 471,270 | 58,574 | 61.6 K to 58.6 K (-4.87 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | LINK MAX | Director | Sell | S | 155.91 | 13,912 | 2,169,020 | 61,574 | 75.5 K to 61.6 K (-18.43 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | LINK MAX | Director | Sell | S | 154.95 | 10,662 | 1,652,077 | 75,486 | 86.1 K to 75.5 K (-12.38 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | LINK MAX | Director | Sell | S | 154.02 | 12,426 | 1,913,853 | 86,148 | 98.6 K to 86.1 K (-12.61 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 153.63 | 2,390 | 367,176 | 105,830 | 108.2 K to 105.8 K (-2.21 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 157.14 | 729 | 114,555 | 108,220 | 108.9 K to 108.2 K (-0.67 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Sell | S | 153.63 | 760 | 116,759 | 8,703 | 9.5 K to 8.7 K (-8.03 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 153.63 | 8,870 | 1,362,698 | 963,276 | 972.1 K to 963.3 K (-0.91 %) |
Feb 05 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 157.14 | 2,920 | 458,849 | 972,146 | 975.1 K to 972.1 K (-0.30 %) |
Jan 31 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 133.21 | 18 | 2,398 | 103,068 | 103.1 K to 103.1 K (-0.02 %) |
Jan 31 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 133.31 | 1,100 | 146,641 | 103,086 | 104.2 K to 103.1 K (-1.06 %) |
Jan 31 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 133.37 | 29 | 3,868 | 108,949 | 109 K to 108.9 K (-0.03 %) |
Jan 31 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 133.45 | 700 | 93,415 | 108,978 | 109.7 K to 109 K (-0.64 %) |
Jan 31 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 133.37 | 94 | 12,537 | 133,327 | 133.4 K to 133.3 K (-0.07 %) |
Jan 31 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 133.44 | 900 | 120,096 | 133,421 | 134.3 K to 133.4 K (-0.67 %) |
Jan 31 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 133.72 | 60 | 8,023 | 975,066 | 975.1 K to 975.1 K (-0.01 %) |
Jan 31 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 133.81 | 2,600 | 347,906 | 975,126 | 977.7 K to 975.1 K (-0.27 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 10.29 | 12,817 | 131,887 | 130,280 | |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 10.29 | 17,183 | 176,813 | 143,097 | |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 8.18 | 65,936 | 539,356 | 0 | |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 6.90 | 27,811 | 191,896 | 0 | |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 6.90 | 32,689 | 225,554 | 27,811 | |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 142.05 | 2,093 | 297,311 | 977,726 | 979.8 K to 977.7 K (-0.21 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 141.28 | 10,724 | 1,515,087 | 979,819 | 990.5 K to 979.8 K (-1.08 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 10.29 | 12,817 | 131,887 | 990,543 | 977.7 K to 990.5 K (+1.31 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 142.46 | 16,008 | 2,280,500 | 977,726 | 993.7 K to 977.7 K (-1.61 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 141.64 | 32,330 | 4,579,221 | 993,734 | 1 M to 993.7 K (-3.15 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 140.60 | 27,453 | 3,859,892 | 1,026,064 | 1.1 M to 1 M (-2.61 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 139.79 | 35,139 | 4,912,081 | 1,053,517 | 1.1 M to 1.1 M (-3.23 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 10.29 | 17,183 | 176,813 | 1,088,656 | 1.1 M to 1.1 M (+1.60 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 8.18 | 65,936 | 539,356 | 1,137,409 | 1.1 M to 1.1 M (+6.15 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 6.90 | 27,811 | 191,896 | 1,071,473 | 1 M to 1.1 M (+2.66 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 140.94 | 2,287 | 322,330 | 1,043,662 | 1 M to 1 M (-0.22 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 140.14 | 30,402 | 4,260,536 | 1,045,949 | 1.1 M to 1 M (-2.82 %) |
Jan 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 6.90 | 32,689 | 225,554 | 1,076,351 | 1 M to 1.1 M (+3.13 %) |
Jan 15 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 6.90 | 15,845 | 109,331 | 60,500 | |
Jan 15 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 135.25 | 15,845 | 2,143,036 | 1,043,662 | 1.1 M to 1 M (-1.50 %) |
Jan 15 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 6.90 | 15,845 | 109,331 | 1,059,507 | 1 M to 1.1 M (+1.52 %) |
Jan 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 6.90 | 11,705 | 80,765 | 76,345 | |
Jan 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 6.90 | 1,039 | 7,169 | 88,050 | |
Jan 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 6.90 | 911 | 6,286 | 89,089 | |
Jan 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 5.18 | 5,500 | 28,490 | 0 | |
Jan 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 135.00 | 11,705 | 1,580,175 | 1,031,957 | 1 M to 1 M (-1.12 %) |
Jan 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 6.90 | 11,705 | 80,765 | 1,043,662 | 1 M to 1 M (+1.13 %) |
Jan 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 135.05 | 1,039 | 140,317 | 1,031,957 | 1 M to 1 M (-0.10 %) |
Jan 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 6.90 | 1,039 | 7,169 | 1,032,996 | 1 M to 1 M (+0.10 %) |
Jan 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 134.93 | 6,411 | 865,036 | 1,031,957 | 1 M to 1 M (-0.62 %) |
Jan 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 6.90 | 911 | 6,286 | 1,038,368 | 1 M to 1 M (+0.09 %) |
Jan 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 5.18 | 5,500 | 28,490 | 1,037,457 | 1 M to 1 M (+0.53 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | M | 17.98 | 15,363 | 276,227 | 0 | |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | M | 17.98 | 7,295 | 131,128 | 0 | |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 127.61 | 15,363 | 1,960,472 | 109,678 | 125 K to 109.7 K (-12.29 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Grant | A | 17.98 | 15,363 | 276,227 | 125,041 | 109.7 K to 125 K (+14.01 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 127.53 | 7,295 | 930,331 | 109,678 | 117 K to 109.7 K (-6.24 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Buy | M | 17.98 | 7,295 | 131,164 | 116,973 | 109.7 K to 117 K (+6.65 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Option Exercise | M | 17.65 | 32,026 | 565,259 | 1,832 | |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 127.81 | 32,026 | 4,093,243 | 134,321 | 166.3 K to 134.3 K (-19.25 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Buy | M | 17.65 | 32,026 | 565,259 | 166,347 | 134.3 K to 166.3 K (+23.84 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 5.18 | 35,000 | 181,300 | 5,500 | |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 17.65 | 5,664 | 99,970 | 0 | |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 5.18 | 57,500 | 297,850 | 40,500 | |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 5.10 | 82,500 | 420,750 | 0 | |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 129.90 | 35,000 | 4,546,500 | 1,031,957 | 1.1 M to 1 M (-3.28 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 5.18 | 35,000 | 181,300 | 1,066,957 | 1 M to 1.1 M (+3.39 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 128.59 | 14,415 | 1,853,625 | 1,031,957 | 1 M to 1 M (-1.38 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 127.44 | 9,736 | 1,240,756 | 1,046,372 | 1.1 M to 1 M (-0.92 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 126.33 | 5,872 | 741,810 | 1,056,108 | 1.1 M to 1.1 M (-0.55 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 125.30 | 73,843 | 9,252,528 | 1,061,980 | 1.1 M to 1.1 M (-6.50 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 124.31 | 24,273 | 3,017,377 | 1,135,823 | 1.2 M to 1.1 M (-2.09 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 123.35 | 11,861 | 1,463,054 | 1,160,096 | 1.2 M to 1.2 M (-1.01 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 17.65 | 5,664 | 99,970 | 1,171,957 | 1.2 M to 1.2 M (+0.49 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 5.18 | 57,500 | 297,850 | 1,166,293 | 1.1 M to 1.2 M (+5.19 %) |
Dec 20 2013 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 5.10 | 82,500 | 420,750 | 1,108,793 | 1 M to 1.1 M (+8.04 %) |
Dec 11 2013 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Buy | P | 84.95 | 140 | 11,893 | 7,451 | 7.3 K to 7.5 K (+1.91 %) |
Dec 11 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | M | 17.98 | 14,637 | 263,173 | 15,363 | |
Dec 11 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | M | 17.98 | 10,705 | 192,422 | 7,295 | |
Dec 11 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 127.63 | 14,637 | 1,868,120 | 109,678 | 124.3 K to 109.7 K (-11.77 %) |
Dec 11 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Buy | M | 17.98 | 14,637 | 263,173 | 124,315 | 109.7 K to 124.3 K (+13.35 %) |
Dec 11 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 127.63 | 10,705 | 1,366,279 | 109,678 | 120.4 K to 109.7 K (-8.89 %) |
Dec 11 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Buy | M | 17.98 | 10,705 | 192,476 | 120,383 | 109.7 K to 120.4 K (+9.76 %) |
Dec 11 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Option Exercise | M | 17.65 | 17,974 | 317,241 | 33,858 | |
Dec 11 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 127.66 | 17,974 | 2,294,561 | 134,321 | 152.3 K to 134.3 K (-11.80 %) |
Dec 11 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Buy | M | 17.65 | 17,974 | 317,241 | 152,295 | 134.3 K to 152.3 K (+13.38 %) |
Nov 05 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 42.66 | 6,250 | 266,625 | 0 | |
Nov 05 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 22.90 | 7,875 | 180,338 | 0 | |
Nov 05 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 124.39 | 1,239 | 154,119 | 104,186 | 105.4 K to 104.2 K (-1.18 %) |
Nov 05 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 123.82 | 12,886 | 1,595,545 | 105,425 | 118.3 K to 105.4 K (-10.89 %) |
Nov 05 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 42.66 | 6,250 | 266,625 | 118,311 | 112.1 K to 118.3 K (+5.58 %) |
Nov 05 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 22.90 | 7,875 | 180,338 | 112,061 | 104.2 K to 112.1 K (+7.56 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Option Exercise | M | 17.65 | 50,000 | 882,500 | 51,832 | |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 123.85 | 7,862 | 973,709 | 310,808 | 318.7 K to 310.8 K (-2.47 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 122.80 | 42,138 | 5,174,546 | 318,670 | 360.8 K to 318.7 K (-11.68 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Buy | M | 17.65 | 50,000 | 882,500 | 360,808 | 310.8 K to 360.8 K (+16.09 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | M | 17.98 | 18,000 | 323,550 | 18,000 | |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 123.77 | 7,963 | 985,581 | 88,178 | 96.1 K to 88.2 K (-8.28 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 122.79 | 22,037 | 2,705,923 | 96,141 | 118.2 K to 96.1 K (-18.65 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Buy | M | 17.98 | 30,000 | 539,400 | 118,178 | 88.2 K to 118.2 K (+34.02 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 123.77 | 4,777 | 591,249 | 88,178 | 93 K to 88.2 K (-5.14 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 122.79 | 13,223 | 1,623,652 | 92,955 | 106.2 K to 93 K (-12.45 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Buy | M | 17.98 | 18,000 | 323,640 | 106,178 | 88.2 K to 106.2 K (+20.41 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Gift | G | 0.00 | 24,363 | 0 | 31,781 | 56.1 K to 31.8 K (-43.39 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 93.83 | 7,600 | 713,108 | 7,600 | |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 78.88 | 32,437 | 2,558,631 | 32,437 | |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 123.89 | 1,000 | 123,890 | 104,186 | 105.2 K to 104.2 K (-0.95 %) |
Oct 30 2013 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 124.76 | 500 | 62,380 | 105,186 | 105.7 K to 105.2 K (-0.47 %) |